Hostname: page-component-745bb68f8f-f46jp Total loading time: 0 Render date: 2025-01-11T22:47:11.237Z Has data issue: false hasContentIssue false
  • English
  • Français

The Public Health Value of Opioid Litigation

Published online by Cambridge University Press:  01 January 2021

Rebecca L. Haffajee
Get access Rights & Permissions [Opens in a new window]

Abstract

Opioid litigation continues a growing public health litigation trend in which governments seek to hold companies responsible for population harms related to their products. The litigation can serve to address gaps in regulatory and legislative policymaking and in market self-regulation pervasive in the prescription opioid domain. Moreover, prior opioid settlements have satisfied civil tort litigation objectives of obtaining compensation for injured parties, deterring harmful behavior, and holding certain opioid manufacturers, distributors and pharmacies accountable for their actions. In this way, opioid litigation represents progress over prior public health litigation campaigns involving tobacco, lead paint, and asbestos, which had more limited tort litigation effects. Although opioid litigation is not a comprehensive solution to the opioid crisis, it can complement other strategies and infuse much needed money, behavior changes, and public accountability for prescription opioid and related harms.

Type
Symposium Articles
Information
Journal of Law, Medicine & Ethics , Volume 48 , Issue 2: Opioid Controversies: The Crisis — Causes and Solutions , Summer 2020 , pp. 279 - 292
Copyright
Copyright © American Society of Law, Medicine & Ethics 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Endnotes

Gostin, L.O. and Wiley, L.F., Public Health Law: Power, Duty, Restraint (Oakland: University of California Press, 2016): at 227.CrossRefGoogle Scholar
Hedegaard, H., Miniño, A.M., and Warner, M., “Drug Overdose Deaths in the United States, 1999–2017,” National Center for Health Statistics Data Brief 329 (Nov. 2018), available at <https://www.cdc.gov/nchs/products/databriefs/db329.htm> (last visited April 14, 2020).+(last+visited+April+14,+2020).>Google Scholar
Gluck, A.R., Hall, A., and Curfman, G., “Civil Litigation and the Opioid Epidemic: The Role of Courts in a National Health Crisis,” Journal of Law, Medicine & Ethics 46, no. 2 (2018): 351-366, at 359-360; Raymond, N., “NY Accuses Opioid Maker Purdue of Illegal Funds Transfers to Sacklers,” Reuters, Mar. 28, 2019, available at <https://www.reuters.com/article/us-usa-opioids-litigation/n-y-accuses-opioid-maker-purdue-of-illegal-fund-transfers-to-sacklers-idUSKCN1R9220> (last visited April 14, 2020).Google Scholar
Haffajee, R.L. and Mello, M.M., “Drug Companies' Liability for the Opioid Epidemic,” N. Engl. J. Med. 377, no. 24 (2017): 2301-2305, at 2302-2303; See Gostin and Wiley, supra note 1, at 229-46.CrossRefGoogle Scholar
Diep, F., “What Oklahoma's $270 Million Settlement with Purdue Pharma Means for the 1,000-Plus Opioid Cases Still Pending,” Pacific Standard, Mar. 27, 2019, available at <https://psmag.com/news/what-oklahomas-settlement-with-purdue-pharma-means-for-opioid-cases> (last visited April 14, 2020); Feeley, J., “More States Could Settle Opioid Suits in Wake of West Virginia's McKesson Deal,” Insurance Journal, May 6, 2019, available at <https://www.insurancejournal.com/news/national/2019/05/06/525515.htm> (last visited April 14, 2020); Company Statement, “Teva Reaches Agreement with State of Oklahoma to Resolve State's Claim Against the Company,” Associated Press, May 26, 2019, available at <https://www.apnews.com/Business%20Wire/e3cbd00425694f2eb-6ba2725620022db> (last visited April 14, 2020); Becker, S. and Smith, E., “Oklahoma Judge Miscalculated How Much Johnson & Johnson Would Pay for the State's Opioid Crisis,” CNN, October 16, 2019, available at <https://www.cnn.com/2019/10/15/health/oklahoma-opioid-judgment-miscalculation/index.html> (last visited April 14, 2020). (last visited April 14, 2020); Feeley, J., “More States Could Settle Opioid Suits in Wake of West Virginia's McKesson Deal,” Insurance Journal, May 6, 2019, available at (last visited April 14, 2020); Company Statement, “Teva Reaches Agreement with State of Oklahoma to Resolve State's Claim Against the Company,” Associated Press, May 26, 2019, available at (last visited April 14, 2020); Becker, S. and Smith, E., “Oklahoma Judge Miscalculated How Much Johnson & Johnson Would Pay for the State's Opioid Crisis,” CNN, October 16, 2019, available at (last visited April 14, 2020).' href=https://scholar.google.com/scholar?q=Diep,+F.,+“What+Oklahoma's+$270+Million+Settlement+with+Purdue+Pharma+Means+for+the+1,000-Plus+Opioid+Cases+Still+Pending,”+Pacific+Standard,+Mar.+27,+2019,+available+at++(last+visited+April+14,+2020);+Feeley,+J.,+“More+States+Could+Settle+Opioid+Suits+in+Wake+of+West+Virginia's+McKesson+Deal,”+Insurance+Journal,+May+6,+2019,+available+at++(last+visited+April+14,+2020);+Company+Statement,+“Teva+Reaches+Agreement+with+State+of+Oklahoma+to+Resolve+State's+Claim+Against+the+Company,”+Associated+Press,+May+26,+2019,+available+at++(last+visited+April+14,+2020);+Becker,+S.+and+Smith,+E.,+“Oklahoma+Judge+Miscalculated+How+Much+Johnson+&+Johnson+Would+Pay+for+the+State's+Opioid+Crisis,”+CNN,+October+16,+2019,+available+at++(last+visited+April+14,+2020).>Google Scholar
Bernstein, L., et al., “Last-Ditch Opioid Settlement in Ohio Could Open Door for Much Larger Deal,” The Washington Post, October 21, 2019, available at <https://www.washington-post.com/health/ohio-counties-drug-firms-reach-260m-settlement-averting-trial/2019/10/21/c9ac1dd4-f39f-11e9-ad8b-85e2aa00b5ce_story.html> (last visited April 14, 2020).+(last+visited+April+14,+2020).>Google Scholar
Carr, D., Davis, C.S., and Rutkow, L., “Reducing Harm through Litigation against Opioid Manufacturers? Lessons from the Tobacco Wars,” Public Health Reports 133, no. 2 (2018): 207-213, at 209-210.CrossRefGoogle Scholar
See Gostin and Wiley, supra note 1, at 228-229; Parmet, W.E. and Daynard, R.A., “The New Public Health Litigation,” Annual Review of Public Health 21 (2000): 437–54, at 439-441.CrossRefGoogle Scholar
Haffajee and Mello, supra note 4, at 2301-2305; See Gostin and Wiley, supra note 1, at 229-46.Google Scholar
See Gostin and Wiley, supra note 1, at 227.Google Scholar
Id.; Jacobson, P.D. and Warner, K.E., “Litigation and Public Health Policy Making: The Case of Tobacco Control,” Journal of Health Politics, Policy & Law 24, no. 4 (1999): 769-804, at 793-795.Google Scholar
Rosenberg, G.N., The Hollow Hope: Can Courts Bring About Social Change (Chicago: University of Chicago Press, 1991): at 39-69.Google Scholar
Id. at 39-69.Google Scholar
See Jacobson and Warner, supra note 11, at 772.Google Scholar
See Parmet and Daynard, supra note 8, at 446-447.Google Scholar
See Jacobson and Warner, supra note 11, at 772-773.Google Scholar
See generally National Association of Attorneys General, Master Settlement Agreement (2014), available at <http://www.naag.org/assets/redesign/files/msa-tobacco/MSA.pdf> (last visited April 14, 2020); Tobacco Control Legal Consortium, Public Health Law Center, The Master Settlement Agreement: An Overview (2015), available at <http://www.publichealthlawcenter.org/sites/default/files/resources/tclc-fsmsa-overview-2015.pdf> (last visited April 14, 2020).+(last+visited+April+14,+2020);+Tobacco+Control+Legal+Consortium,+Public+Health+Law+Center,+The+Master+Settlement+Agreement:+An+Overview+(2015),+available+at++(last+visited+April+14,+2020).>Google Scholar
See Jacobson and Warner, supra note 11, at 779.Google Scholar
Id. at 784; see generally FDA v. Brown & Williamson Tobacco Corp., 529 U.S. 120 (2000).Google Scholar
Pringle, P., “The Chronicles of Tobacco: An Account of the Forces that Brought the Tobacco Industry to the Negotiating Table,” William Mitchell Law Review 25, no. 2 (1999): 387-395, at 387-388.Google Scholar
Family Smoking Prevention and Tobacco Control Act, Pub.L. 111–31, H.R. 1256 (2009).Google Scholar
Healton, C., “The Tobacco Master Settlement Agreement—Strategic Lessons for Addressing Public Health Problems,” N. Eng. J. Med. 379, no. 11 (2018): 997-1000, at 997.CrossRefGoogle Scholar
U.S. Government Accountability Office, “States' Allocations of Payments from the Tobacco Companies for Fiscal Years 2000 through 2005,” GAO-07-534T (2007), at 6, available at <https://www.gao.gov/assets/120/115580.pdf> (last visited April 14, 2020); Haile, A.J. and Krueger-Andes, M.W., “Landmark Settlements and Unintended Consequences,” University of Toledo Law Review 44, no. 1 (2012): 145-178, at 146; Jones, W.J. and Silvestri, G., “The Master Settlement Agreement and its Impact on Tobacco Use 10 Years Later: Lessons for Physicians about Health Policy Making,” Chest 137, no. 3 (2010): 692-700, at 694.Google Scholar
See Carr et al., supra note 7, at 212; U.S. Government Accountability Office, supra note 24, at 6; Jones and Sylvestri, supra note 24, at 694-697.Google Scholar
See Jones and Sylvestri, supra note 23, at 697; Parmet and Daynard, supra note 8, at 447; Jacobson and Warner, supra note 11, at 787.Google Scholar
Schroeder, S.A., “Tobacco Control in the Wake of the 1998 Master Settlement Agreement,” N. Eng. J. Med. 350, no. 3 (2004): 293-301, at 296-297; see Jacobson and Warner, supra note 11, at 788-789; Carr et al., supra note 7, at 212.CrossRefGoogle Scholar
See Jacobson and Warner, supra note 11, at 788; University of San Francisco Library and Center for Knowledge Management, “Truth Tobacco Industry Documents,” available at <https://www.industrydocuments.ucsf.edu/tobacco/> (last visited April 14, 2020).+(last+visited+April+14,+2020).>Google Scholar
See Jacobson and Warner, supra note 11, at 788.Google Scholar
See Jones and Sylvestri, supra note 23, at 695.CrossRefGoogle Scholar
Mesothelioma and Asbestos Awareness Center, “Asbestos,” last updated May 13, 2019, available at <https://www.maacenter.org/asbestos/> (last visited April 14, 2020); Hensler, D.R., “Asbestos Litigation in the United States: Triumph and Failure of the Civil Justice System,” Connecticut Law Journal 12, no. 2 (2005): 255-280, at 258.Google Scholar
See Hensler, supra note 30, at 258.Google Scholar
White, M.J., “Asbestos and the Future of Mass Torts,” Journal of Economic Perspectives 18, no. 2 (2004): 183-204, at 186.CrossRefGoogle Scholar
Leonardi, J.L., “It's Still Here – the Continuing Battle over Asbestos in America,” Villanova Law Review 16, no. 1 (2005): 129-148, at 140; see Hensler, supra note 30, at 259; Mesothelioma and Asbestos Awareness Center, “Asbestos,” last updated May 13, 2019, available at <https://www.maacenter.org/asbestos/> (last visited April 14, 2020).Google Scholar
Borel v. Fibreboard, 493 F.2d 1076, 1093-96 (5th Cir. 1973); Hensler, supra note 30, at 259-61.Google Scholar
See Hensler, supra note 30, at 261-273.Google Scholar
Id. at 261-279.Google Scholar
Id. at 279.Google Scholar
See Leonardi, supra note 33, at 130-131; Hensler, supra note 30, at 279.Google Scholar
Centers for Disease Control and Prevention, “Lead,” last updated Feb. 4, 2019, available at <https://www.cdc.gov/nceh/lead/> (last visited April 14, 2020).+(last+visited+April+14,+2020).>Google Scholar
Smith, S.A., “Turning Lead into Asbestos and Tobacco: Litigation Alchemy Gone Wrong,” Defense Counsel Journal 71, no. 2 (2004): 119-130, at 119.Google Scholar
Tipps, P., “Controlling the Lead Paint Debate: Why Control is Not an Element of Public Nuisance,” Boston College Law Review 50, no. 2 (2009): 605-638, at 621-624.Google Scholar
Id. at 609-10.Google Scholar
Hiltzik, M., “This Lawsuit to Force Lead Paint Makers to Clean Up California Homes Has been in Court for 17 Years,” L.A. Times, Apr. 21, 2017, available at <https://www.latimes.com/business/hiltzik/la-fi-hiltzik-lead-paint-case-20170423-story.html> (last visited April 14, 2020); Hiltik, M., “In Landmark Ruling, Court Orders Paint Companies to Pay to Clean Lead Paint Out of California Homes,” L.A. Times, Nov. 15, 2017, available at <https://www.latimes.com/business/hiltzik/lafi-hiltzik-lead-paint-ruling-20171115-story.html> (last visited April 14, 2020).+(last+visited+April+14,+2020);+Hiltik,+M.,+“In+Landmark+Ruling,+Court+Orders+Paint+Companies+to+Pay+to+Clean+Lead+Paint+Out+of+California+Homes,”+L.A.+Times,+Nov.+15,+2017,+available+at++(last+visited+April+14,+2020).>Google Scholar
Haffajee and Mello, supra note 4, at 2302-2303.Google Scholar
Id. at 2302-2303; Gluck et al., supra note 3, at 355.Google Scholar
Haffajee and Mello, supra note 4, at 2302-2303; Gluck et al., supra note 3, at 355-356.Google Scholar
Haffajee and Mello, supra note 4, at 2302-2305.Google Scholar
Id.Google Scholar
Id.Google Scholar
Id.; Gluck, supra note 3, at 355-358.Google Scholar
Belmonte, A., “How an American Billionaire Predicted — and Then Profited from — an Oxycontin ‘Prescription Blizzard’,” Yahoo Finance, Jun. 12, 2019, available at <https://finance.yahoo.com/news/opioid-crisis-purdue-sacklers-141623926.html> (last visited April 14, 2020); Mann, B., “Partisan Divide Grows over Opioid Settlement Plan,” National Public Radio, October 20, 2019, available at <https://www.npr.org/2019/10/20/771364817/partisan-divide-grows-over-opioid-settlement-plan> (last visited April 14, 2020).+(last+visited+April+14,+2020);+Mann,+B.,+“Partisan+Divide+Grows+over+Opioid+Settlement+Plan,”+National+Public+Radio,+October+20,+2019,+available+at++(last+visited+April+14,+2020).>Google Scholar
Ausness, J., “Litigation Against Drug Companies Is Ineffective,” Presentation at the 25th Annual Thomas Pitts Lecture-ship in Medical Ethics, Medical University of South Carolina, Charleston, South Carolina, April 4, 2019.Google Scholar
In Re: National Prescription Opiate Litigation, Transcript of Proceedings before the Honorable Dan A. Polster United States District Judge and before the Honorable David A. Ruiz United States Magistrate Judge, U.S. District Court Northern District of Ohio, MDL No. 2804 Case No. 1:17-CV-2804, Cleveland, Ohio, January 9, 2018: at 4.Google Scholar
Haffajee, R.L. and Frank, R.G., “Making the Opioid Emergency Effective,” JAMA Psychiatry 75, no. 8 (2018): 767-768, at 767-768; Haffajee, R.L. and French, C.A., “Provider Perceptions of System-Level Opioid Prescribing and Addiction Treatment Policies,” Current Opinions in Psychology 30 (2019): 65-73, at 66.Google Scholar
Whitaker, B., “Ex-DEA Agent: Opioid Crisis Fueled by Drug Industry and Congress,” 60 Minutes, June 17, 2018, available at <https://www.cbsnews.com/news/60-minutes-ex-dea-agent-opioid-crisis-fueled-by-drug-industry-and-congress/> (last visited April 14, 2020); Higham, S. and Bernstein, L., “The Drug Industry's Triumph Over the DEA,” Washington Post, Oct. 15, 2017, available at <https://www.washington-post.com/graphics/2017/investigations/dea-drug-industry-congress/?noredirect=on&utm_term=.cb05f50ac55b> (last visited April 14, 2020). (last visited April 14, 2020).' href=https://scholar.google.com/scholar?q=Whitaker,+B.,+“Ex-DEA+Agent:+Opioid+Crisis+Fueled+by+Drug+Industry+and+Congress,”+60+Minutes,+June+17,+2018,+available+at++(last+visited+April+14,+2020);+Higham,+S.+and+Bernstein,+L.,+“The+Drug+Industry's+Triumph+Over+the+DEA,”+Washington+Post,+Oct.+15,+2017,+available+at++(last+visited+April+14,+2020).>Google Scholar
Editorial Board, “Locating Blame in the Opioid Epidemic,” Washington Post, Oct. 30, 2016, available at <https://www.washingtonpost.com/opinions/is-the-dea-partly-to-blame-forthe-opioid-epidemic/2016/10/30/2fd5dc30-9c78-11e6-b3c9-f662adaa0048_story.html?utm_term=.4552b1f57ae0> (last visited April 14, 2020).+(last+visited+April+14,+2020).>Google Scholar
Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid Abuse, Pain Management and the Opioid Epidemic (Bonnie, R. J. et al., eds., 2017): at 359-409; Zettler, P.J., “Implementing a Public Health Perspective in FDA Drug Regulation,” Food and Drug Law Journal 73, no. 2 (2018): 221-256, at 235-255; Frydl, K.J., “The Enemy is Us: The Opioid Crisis and the Failure of Politics,” Dissent Magazine, Apr. 20, 2017, available at <https://www.dissentmagazine.org/online_articles/opioid-crisis-failure-politics-fda-neoliberalism> (last visited April 14, 2020).Google Scholar
Id.Google Scholar
Manchikanti, L., et al., “Zohydro Approval by Food and Drug Administration: Controversial or Frightening?” Pain Physician 17, no. 4 (2014): E37-50 at E37-E50; Gottlieb, S., “Statement from FDA Commissioner Scott Gottlieb, M.D., on agency's approval of Dsuvia and the FDA's future consideration of new opioids,” (Nov. 2, 2018), available at <https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-agencys-approval-dsuviaand-fdas-future-consideration> (last visited April 14, 2020); Sarpatwari, A., Sinha, M.S., and Kesselheim, A.S., “The Opioid Epidemic: Fixing a Broken Pharmaceutical Market,” Harvard Law and Policy Review 11, no. 2 (2017): 463-484, at 470.Google Scholar
Sekerka, L.E. and Benishek, L., “Thick as Thieves? Big Pharma Wields its Power with the Health of Government Regulation,” Emory Corporate Governance and Accountability Review 5, no. 2 (2018): 113-141, at 123-132; Frydl, supra note 57; Higham and Bernstein, supra note 55.Google Scholar
Silverman, E., “Scott Gottlieb Walks through the Revolving Door to the Pfizer Board,” STAT News, June 27, 2019, available at <https://www.statnews.com/pharmalot/2019/06/27/scott-gottlieb-pfizer-board-fda/?utm_source=STAT+Newsletters&utm_campaign=fae647e51b-Daily_Recap&utm_medium=email&utm_term=0_8cab1d7961-fae647e51b-150070213> (last visited April 14, 2020).+(last+visited+April+14,+2020).>Google Scholar
Whoriskey, P., “Pharmaceutical Firms Paid to Attend Meetings of Panel that Advises DA, Emails Show,” Washington Post, October 6, 2013; Higham and Bernstein, supra note 55.Google Scholar
Van Zee, A., “The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health Tragedy,” American Journal of Public Health 99, no. 2 (2009): 221-227, at 222-223.CrossRefGoogle Scholar
Id.Google Scholar
Id.Google Scholar
Id.; Haffajee, R.L., “Preventing Opioid Misuse with Prescription Drug Monitoring Programs: A Framework for Evaluating the Success of State Public Health Laws,” Hastings Law Journal 67, no. 6 (2016): 1621-1694, at 1627-1628.Google Scholar
Van Zee, supra note 63, at 223.Google Scholar
Department of Justice, U.S. Attorney's Office, District of Massachusetts, “Press Release: Founder and Four Executives of Insys Therapeutics Convicted of Racketeering Conspiracy: First successful prosecution of top pharmaceutical executives for crimes related to the prescribing of opioids (May 2, 2019), available at <https://www.justice.gov/usao-ma/pr/founder-and-four-executives-insys-therapeutics-convicted-racketeering-conspiracy> (last visited April 14, 2020); Subsys Rap Video Created by Insys Pharmaceuticals (Feb. 18, 2019), available at <https://www.youtube.com/watch?v=mtwFZwjCSTE> (last visited April 14, 2020). (last visited April 14, 2020); Subsys Rap Video Created by Insys Pharmaceuticals (Feb. 18, 2019), available at (last visited April 14, 2020).' href=https://scholar.google.com/scholar?q=Department+of+Justice,+U.S.+Attorney's+Office,+District+of+Massachusetts,+“Press+Release:+Founder+and+Four+Executives+of+Insys+Therapeutics+Convicted+of+Racketeering+Conspiracy:+First+successful+prosecution+of+top+pharmaceutical+executives+for+crimes+related+to+the+prescribing+of+opioids+(May+2,+2019),+available+at++(last+visited+April+14,+2020);+Subsys+Rap+Video+Created+by+Insys+Pharmaceuticals+(Feb.+18,+2019),+available+at++(last+visited+April+14,+2020).>Google Scholar
Consent Judgment, State of Washington v. Purdue Pharma L.P., No. 07-2-00917-2 (Wash. Ct. Sup. May 9, 2007), at 14.Google Scholar
Carr, supra note 8, at 208; Examining the Opioid Epidemic: Challenges and Opportunities, Hearing before the U.S. Senate Committee on Finance, 114th Cong. (2016) 11.Google Scholar
Consent Judgment, State of Oklahoma v. Purdue Pharma L.P., No. CJ-2017-816 (Dis. Ct. Cleveland County, State of Oklahoma, March 26 2019), at 10; Judgment after Non-Jury Trial, State of Oklahoma v. Purdue Pharma, L.P., No. CJ-2017-816 (Dis. Ct. Cleveland County, State of Oklahoma, August 26, 2019)Google Scholar
Rhyan, C., “Economic Toll of Opioid Crisis in U.S. Exceeded $1 Trillion Since 2001” (2018), available at <https://altarum.org/news/economic-toll-opioid-crisis-us-exceeded-1-trillion-2001> (last visited April 14, 2020); Manchikanti, L. et al., “Opioid Epidemic in the United States,” Pain Physician 15, no. 3 suppl (2012): ES9-ES38, at ES10; The Council of Economic Advisers, “The Underestimated Cost of the Opioid Crisis” (2017), at 1, available at <https://www.whitehouse.gov/sites/whitehouse.gov/files/images/The%20Underestimated%20Cost%20of%20the%20Opioid%20Crisis.pdf> (last visited April 14, 2020); Florence, C. et al., “The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States,” Medical Care 54, no. 10 (2016): 901-906, at 901.Google Scholar
Rhyan, C., “The Potential Societal Benefit of Eliminating Opioid Overdoses, Deaths, and Substance Use Disorders Exceeds $95 Billion per Year” (2017), available at <https://altarum.org/sites/default/files/uploaded-publication-files/Research-Brief_Opioid-Epidemic-Economic-Burden.pdf> (last visited April 14, 2020).+(last+visited+April+14,+2020).>Google Scholar
Bernstein, supra note 5.Google Scholar
Consent Judgment, State of Oklahoma v. Purdue Pharma L.P., No. CJ-2017-816 (Dis. Ct. Cleveland County, State of Oklahoma, March 26 2019), at 10.Google Scholar
Oklahoma Attorney General's Office, “Press Release: Attorney General Hunter Announces Historic $270 Million Settlement with Purdue Pharma, $200 Million to Establish Endowment for OSU Center for Wellness,” March 26, 2019, available at <http://www.oag.ok.gov/attorney-general-hunter-announces-historic-270-million-settlement-with-purdue-pharma-200-million-to-establish-endowment-for-osu-center-forwellness> (last visited April 14, 2020). (last visited April 14, 2020).' href=https://scholar.google.com/scholar?q=Oklahoma+Attorney+General's+Office,+“Press+Release:+Attorney+General+Hunter+Announces+Historic+$270+Million+Settlement+with+Purdue+Pharma,+$200+Million+to+Establish+Endowment+for+OSU+Center+for+Wellness,”+March+26,+2019,+available+at++(last+visited+April+14,+2020).>Google Scholar
Consent Judgment, State of Oklahoma v. Purdue Pharma L.P., No. CJ-2017-816 (Dis. Ct. Cleveland County, State of Oklahoma, March 26 2019), at 10.Google Scholar
Bernstein, L., “In Oklahoma, Opioid Case Windfall Starts Winners Squabbling,” The Washington Post, June 20, 2019, available at <https://www.washingtonpost.com/health/in-oklahoma-opioid-case-windfall-starts-winners-squabbling/2019/06/20/92ce0f60-92bb-11e9-b570-6416efdc0803_story.html> (last visited April 14, 2020).+(last+visited+April+14,+2020).>Google Scholar
Haffajee and Mello, supra note 4, at 2302-2303; Silverman, E., “Insys Therapeutics, Opioid Maker Implicated in Major Kickback Scheme, Files for Bankruptcy,” STAT News, June 10, 2019, available at <https://www.statnews.com/pharmalot/2019/06/10/insys-opioids-bankruptcy-subsys/> (last visited April 14, 2020); Spector, M., DiNapoli, J., Raymond, N., “OxyContin maker Purdue Pharma exploring bankruptcy – sources,” Reuters, March 4, 2019, available at <https://www.reuters.com/article/uk-purduepharma-bankruptcy-exclusive/exclusive-oxycontin-maker-purdue-pharma-exploring-bankruptcy-sources-idUSKCN1QL1KP> (last visited April 14, 2020).+(last+visited+April+14,+2020);+Spector,+M.,+DiNapoli,+J.,+Raymond,+N.,+“OxyContin+maker+Purdue+Pharma+exploring+bankruptcy+–+sources,”+Reuters,+March+4,+2019,+available+at++(last+visited+April+14,+2020).>Google Scholar
Mann, supra note 51.Google Scholar
Haffajee and Mello, supra note 4, at 2302-2303.Google Scholar
Cardinal Health, “Press Release: Cardinal Health Foundation Awards Over $3 Million to More than 70 Nonprofit Organizations to Fight the Opioid Epidemic Across Appalachia,” June 19, 2018, available at <http://cardinalhealth.mediaroom.com/GenRx_grants> (last visited April 14, 2020); McKesson Corporation, “Press Release: McKesson Announces New Initiatives, Launches Foundation to Help Fight Nation's Opioid Epidemic,” March 29, 2018, available at <https://www.mckesson.com/about-mckesson/newsroom/press-releases/2018/new-initiatives-fight-opioid-epidemic/> (last visited April 14, 2020); Purdue Pharma, “Purdue's Efforts to Help Address the Crisis,” 2019, available at <https://www.purdueopioidinfo.com/policy-actions/> (last visited April 14, 2020). (last visited April 14, 2020); Purdue Pharma, “Purdue's Efforts to Help Address the Crisis,” 2019, available at (last visited April 14, 2020).' href=https://scholar.google.com/scholar?q=Cardinal+Health,+“Press+Release:+Cardinal+Health+Foundation+Awards+Over+$3+Million+to+More+than+70+Nonprofit+Organizations+to+Fight+the+Opioid+Epidemic+Across+Appalachia,”+June+19,+2018,+available+at++(last+visited+April+14,+2020);+McKesson+Corporation,+“Press+Release:+McKesson+Announces+New+Initiatives,+Launches+Foundation+to+Help+Fight+Nation's+Opioid+Epidemic,”+March+29,+2018,+available+at++(last+visited+April+14,+2020);+Purdue+Pharma,+“Purdue's+Efforts+to+Help+Address+the+Crisis,”+2019,+available+at++(last+visited+April+14,+2020).>Google Scholar
Purdue Pharma, “Purdue's Efforts to Help Address the Crisis,” 2019, available at <https://www.purdueopioidinfo.com/policy-actions/> (last visited April 14, 2020). (last visited April 14, 2020).' href=https://scholar.google.com/scholar?q=Purdue+Pharma,+“Purdue's+Efforts+to+Help+Address+the+Crisis,”+2019,+available+at++(last+visited+April+14,+2020).>Google Scholar
Marketplace Staff and Associated Press, “OxyContin Maker Purdue Pharma to Stop Marketing Opioids to Doctors,” Marketplace, February 10, 2018, available at <https://www.marketplace.org/2018/02/10/oxycontin-maker-purdue-pharma-stop-marketing-opioids-doctors/> (last visited April 14, 2020).+(last+visited+April+14,+2020).>Google Scholar
U.S. Senate Committee on Homeland Security and Governmental Affairs, “McCaskill Report Shows 1.6 Billion Opioid Doses Entered Missouri from 2012-2017,” July 12, 2018, available at <https://www.hsgac.senate.gov/media/minority-media/breaking-mccaskill-report-shows-16-billion-opioid-doses-entered-missouri-from-2012-2017> (last visited April 14, 2020).+(last+visited+April+14,+2020).>Google Scholar
Mauri, A.I., Townsend, T. N., and Haffajee, R. L., “The Association of State Opioid Misuse Prevention Policies with Patient-and Provider-Related Outcomes: A Scoping Review,” Milbank Quarterly 98, no. 1 (2019): 57-105; Haffajee, R.L., “Prescription Drug Monitoring Programs: Friend or Folly in Addressing the Opioid-Overdose Crisis?” N. Eng. J. Med. 381, no. 8 (2019): 699-701, at 699-701.CrossRefGoogle Scholar
Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act of 2018, Pub. L. No. 115-271 (Oct. 24, 2018); Haffajee and French, supra note 54, at 66.Google Scholar